medRxiv preprint doi: https://doi.org/10.1101/2022.08.19.22278986; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetaty.	
It is made available under a CC-BY	4.0 International license .

1	Increased adverse events following third dose of BNT162b2/Pfizer vaccine in
2	those with previous COVID-19, but not with concurrent influenza vaccine.
3	
4	Rachael K. Raw (PhD) <sup>1*</sup> , Jon Rees (MBBS) <sup>2</sup> and David R. Chadwick (PhD) <sup>3</sup>
5	<sup>1</sup> School of Medicine and Health, Newcastle University, Newcastle upon Tyne, UK
6	<sup>2</sup> The School of Psychology, University of Sunderland, UK
7	<sup>3</sup> Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, UK
8	
9	* Corresponding author
10	Rachael Kathleen Raw
11	Email: Rachael.raw3@nhs.net
12	Telephone: +447780652723
13	Manuscript type: Article
14	Key Words: SARS-CoV-2; COVID-19; COVID-19 Vaccination; Vaccine-Associated
15	Adverse Events; Long-COVID; Vaccine Hesitancy; Influenza; Influenza Vaccination.
16	Number of words: 2082
17	Number of references: 20
18	Number of figures: 2
19	Number of tables: 2
20	
21	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 22 Abstract

Prior studies suggest that adverse events (AEs) following doses one and two of 23 BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. To establish 24 whether this outcome applies to a third/booster dose, we conducted a survey with 534 25 26 healthcare workers (HCW) in Northeast England, who reported AEs following all three doses of BNT162b2/Pfizer vaccine. We also explored AEs associated with concurrent seasonal 27 28 influenza immunisation. For all doses of BNT162b2/Pfizer vaccine there was a cluster of systemic AEs that were consistently worse in HCWs with a prior history of COVID-19. AEs 29 30 were no worse in HCWs who received their third/booster dose within 7 days of the influenza jab, rather than further apart. Gender and the presence of ongoing COVID-19 symptoms 31 32 (OCS) had no effect on AEs associated with COVID-19 or influenza vaccination, though 33 younger HCWs experienced more AEs overall. Our findings have implications for vaccine 34 hesitancy and immunisation protocols.

35

### 37 **1. Introduction**

38 Global vaccination efforts against SARS-CoV-2 began in late 2020, with BNT162b2/Pfizer<sup>[1]</sup>, mRNA-1273/Moderna<sup>[2]</sup>, and ChAdOx1/AstraZeneca<sup>[3]</sup> vaccines applied predominantly in the 39 UK population. Healthcare Workers (HCWs) have been a priority target group. Phase three 40 41 trials demonstrated general safety of these vaccines, but adverse events (AEs) have been 42 widely reported, albeit mostly mild-to-moderate in nature and short in duration<sup>[4-10]</sup>. We have previously demonstrated an association between prior COVID-19 infection and increased AEs 43 44 following administration of dose one of BNT162b2/Pfizer vaccine, but not after dose two<sup>[9,10]</sup>. 45 The presence of "ongoing COVID-19 symptoms" (OCS; symptoms persisting from 4-12 weeks)<sup>[11]</sup> was also associated with increased AEs after the second dose of BNT162b2/Pfizer 46 vaccine<sup>[9,10]</sup>. 47

48

49 In late 2021, a 'booster' dose of COVID-19 vaccine was recommended, and as of May 2022, just under 40 million UK citizens had received this third dose<sup>[12]</sup>. To our knowledge, it is 50 unknown whether the previously observed effects of factors such as COVID-19 history carry 51 over to the booster dose. Furthermore, due to the timing of booster vaccinations, many eligible 52 53 individuals, particularly HCWs, were invited to receive their COVID-19 booster at the same time as their seasonal influenza jab, which raises the question of whether concomitant 54 influenza/COVID-19 vaccination may enhance AEs. Large trials have shown that co-55 administration of influenza vaccine with the second dose of a COVID-19 vaccination (including 56 NVX-CoV2373<sup>[13]</sup>, ChAdOx1<sup>[14]</sup> or BNT162b2<sup>[14]</sup>) did not yield any worse AEs than when the 57 COVID-19 vaccine was delivered on its own. No study has yet looked at concomitant 58 administration in the context of the COVID-19 third/booster dose. 59

60

The primary aim of our present study was to explore the impact of risk factors for vaccineassociated AEs following the third/booster dose of BNT162b2/Pfizer vaccine in HCWs. This included prior COVID-19 history, the presence of OCS, and HCWs' age/gender. We also examined whether prior COVID-19 history would lead to worse AEs following the influenza

jab. As a secondary aim, in a small subgroup, we also compared AEs between those who
received their BNT162b2/Pfizer booster around the time of their Influenza jab, and HCWs who
had their vaccinations > 7 days apart.

68

#### 69 **2. Method**

70 HCWs recruited from three Northeast England hospitals, formed an opportunistic sample. 71 HCWs were invited via email to complete an online survey, which captured their experience 72 of AEs following first, second and third/booster doses of the BNT162b2/Pfizer vaccine. AEs 73 were documented using a modified version of the FDA Toxicity Grading Scale.<sup>[15]</sup> as previously 74 described<sup>[9,10]</sup>. HCWs indicated whether they had received influenza vaccine within 7 days of 75 the COVID-19 booster dose. If HCWs did not receive both vaccinations within this time interval, they were also asked to describe AEs following the influenza vaccine. Prior COVID-76 77 19 history was classed as positive for HCWs with self-reported positive PCR and/or COVID-19 test(s). All participants gave their written informed consent, and Cambridge East Research 78 79 Ethics Committee approved this study, which was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. 80

81

The number of moderate-to-severe AEs persisting >24hr were calculated for doses one, two and three of BNT162b2/Pfizer, and for influenza where it was not administered concomitantly. For BNT162b2/Pfizer doses one and two, AEs were only counted as moderate/severe if they were rated as "similar or worse than my current symptoms". Effects of age, gender, presence of OCS, and whether influenza vaccine was administered concomitantly were also considered.

87

Statistical analysis was conducted using JASPv0.16.3.0. Frequencies of categorical variables
and the occurrence of any moderate-to-severe AEs were examined using the chi-square test.
Scores were compared using 2-way ANOVA and ANCOVA where age and gender were
relevant. Multivariable logistic regressions were applied to identify the relationship between

92 COVID-19 status and moderate-to-severe AEs, and the Bonferroni correction applied to the
 93 resulting significance/confidence intervals. Correlation/tests of difference explored
 94 associations between AEs and age/gender.

95

#### 96 **3. Results**

Five-hundred and thirty-four HCWs responded to the questionnaires (15% male, mean age
49.6yr [SD-10.6]. Looking at prior COVID-19 history, 147/454 (32.3%) self-reported previous
COVID-19. 492 (92.1%) had received influenza vaccine: 56 HCWs (11.4%) had it within 7
days of their third BNT162b2/Pfizer dose, 292 HCWs (59.4%) had their doses >7 days apart.
144 HCWs (29.3%) did not indicate time interval.

102

103 Initial analyses revealed a significant negative relationship between age and the number of 104 moderate-to-severe AEs following third BNT162b2/Pfizer and influenza vaccines (BNT162b2/Pfizer Kendall's-tau=-0.16; influenza Kendall's-tau=-0.14;both 105 p<0.001). However, for BNT162b2/Pfizer there was no significant relationship between age and number 106 of AEs reported following doses one and two. There was a significant strong positive 107 108 relationship between number of AEs reported for doses one and two (Kendall'stau=0.46;p<0.001), a negative relationship between AEs following doses one and three 109 (Kendall's-tau=-0.13;p<0.001), but no relationship between number of AEs for doses two or 110 three, or between each of doses two and three, and the number of influenza AEs reported. 111 112 There were no significant differences in number of AEs reported by male versus female 113 HCWs, as shown in Table 1.

114

115 - Insert Table 1 -

117 For occurrence of one or more moderate/severe AEs, there was a significant association with previous COVID-19 and BNT162b2/Pfizer dose one (O.R.-1.64[1.13-2.38];p=0.011), dose 118 two (O.R.-1.63[1.12-2.35];p=0.011), dose three (O.R.-2.44[1.67-3.55];p<0.001), and 119 between previous history of COVID-19 and occurrence of AEs following the influenza vaccine 120 121 (O.R.-1.88[1.25–2.82];p=0.002). To investigate the effect of prior COVID-19 on number of AEs following all three BNT162b2/Pfizer vaccines, a two-by-three (AEs x vaccine dose) ANOVA 122 123 was performed. Age and gender were not used as covariates here given the non-significance 124 of relationships identified with doses one and two, as described above. There was an overall 125 main effect of prior COVID-19 (F(1.8, 957.7)=48.63;p<0.001), whereby HCWs with prior COVID-19 reported 2.59 [2.39-2.79] versus 1.91[1.71-2.12] AEs (Figure 1A). There was a 126 significant difference in number of AEs reported following dose one (F(1,527)=19.93;p<0.001), 127 with post-hoc testing (Bonferroni-p<0.05) demonstrating that the number of AEs reported for 128 129 dose three (1.36 [1.14–1.59]) was significantly lower than reported for dose one (2.84[2.61– 3.07]), and dose two (2.55[2.32–2.78]. There was no interaction between vaccine dose and 130 COVID-19 history (Figure 1A). 131

132

To investigate the difference in number of AEs between BNT162b2/Pfizer dose three and the 133 134 influenza vaccine, together with the role of interval between each vaccine, a two-by-two-way ANCOVA (vaccine x dosage interval), with age and gender as covariates (given the significant 135 relationships here with dose three), was performed. Overall, there were significantly more AEs 136 following BNT162b2/Pfizer dose three (1.28[1.07–1.49]), compared to the influenza vaccine 137 (0.81[0.60–1.02]; Figure 1B); AEs F(1,331)=3.86;d=0.28[0.19–0.37];p<0.001), but there was 138 no significant effect of interval between vaccines (F(1,331)=0.02;p=0.88), and no interaction 139 between these variables (F(1,311)=0.61; p=0.44; Figure 1C). 140

141

142 - Insert Figure 1 -

143

144 Given the association between occurrence of any influenza AEs and prior COVID-19, we investigated this further. A two-by-two-way ANCOVA (vaccine-type x prior COVID-19) was 145 146 performed, with age and gender as covariates. The overall significant difference in number of AEs between prior COVID-19 and influenza was maintained (F(1,470)=1.06;p<0.001), but 147 there was also a significant overall effect of prior COVID-19 with those previously symptomatic 148 reporting more AEs across both types of vaccine (F(1,470)=11.73,p<0.001), but crucially a 149 150 significant interaction between vaccine type and COVID-19 history F(1,470)=4.16;p=0.04). A simple effects analysis revealed this interaction was due to significantly larger numbers of AEs 151 to BNT162b2/Pfizer vaccine in those with prior COVID-19 (t(527)=3.61,p<0.001;d=0.34[0.15-152 0.52]), whilst the difference in number of AEs following influenza vaccine was not significant 153 154 (t (488)=1.78;p=0.08;d=0.17[-0.02-0.36]).

155

A similar pattern of results was found for prolonged AEs, which were scored as total number 156 of vaccine-associated AEs rated as moderate/severe, lasting >24 hours. In this instance, an 157 ANCOVA found significantly higher numbers of prolonged AEs associated with 158 159 BNT162b2/Pfizer vaccine compared to influenza (1.09[0.96-1.23] v 0.32[0.19-0.45]; AEs F(1,511)=15.24;p<0.001), a higher number of prolonged AEs in those with prior COVID-19, 160 161 than without  $(0.84[0.69-1.00] \times 0.57[0.42-0.72]$ ; AEs (F(1,511)=4.09;p=0.044), and a significant interaction between these variables (F(1,511)-7.13;p=0.008). A simple effects 162 analysis showed that the number of prolonged moderate-to-severe AEs was again only 163 significantly higher following BNT162b2/Pfizer vaccine (t(528)=3.03;d=0.28[0.10-164 0.47];p=0.003), with no significant difference in prolonged AEs for the influenza vaccine 165 (t(532)=0.44;d=0.04[-0.14-0.22];p=0.66). 166

167

168 Incidence of each type of AE following BNT162b2/Pfizer dose three for those with and without prior COVID-19, is shown in Table 2. As in our previous work, the cluster of headache, fatigue, 169 myalgia and arthralgia were most common in HCWs with prior COVID-19. Overall, the 170 incidence of AEs to dose three were remarkably like those following the first two doses. 171 172 Looking at the types of AEs most frequently reported, headache, fatigue, and myalgia were associated with prior COVID-19 for the third/booster dose of BNT162b2/Pfizer, after correcting 173 174 for multiple comparisons, age and gender (Figure 2; Table 2). The effect for arthralgia was 175 very nearly significant (p=0.06). A similar analysis for time interval between influenza and 176 BNT162b2/Pfizer dose three, found no significant relationship for occurrence of any of the 177 vaccine-associated AEs (all p>0.9).

178

179 - Insert Table 2 and Figure 2 -

180

Comparing the subset of HCWs with OCS (n=32), with those without OCS, there was a similar 181 reduction in number of AEs to BNT162b2/Pfizer dose three, compared to doses one and two 182 (F(1.82,957.8)=11.89;p<0.001; dose one 2.91[2.41-3.4]; dose two 2.48[1.97-2.98]; dose 183 three 1.44[1.08–1.80]; Bonferroni-corrected post-hoc for dose three being significantly 184 different [p<0.05] to doses one and two. There was no significant overall difference in number 185 186 of AEs between groups (F(1,527)=0.03;p=0.86 (OCS mean 2.30[1.73-2.87]; control mean 2.25[2.10-2.39]), and no significant interaction (F(1.82, 957.8)=0.15;p=0.84). This suggests 187 that OCS had no effect on number of AEs reported at each BNT162b2/Pfizer dose interval. 188 189 Furthermore, there was no significant difference in number of AEs experienced following the 190 influenza jab, between those with versus without OCS (without=0.70;SD-1.5; with=0.56,SD-1.4; AEs d=0.09[-0.30-0.56];p=0.54). 191

193

194

## 195 4. Discussion

196 Our previous work highlighted risk factors for increased BNT162b2/Pfizer vaccine-associated AEs, specifically females, younger age, prior COVID-19, and OCS were associated with 197 198 increased AEs reported following doses one and/or two<sup>[9,10]</sup>. The main findings of our present study were firstly, that frequency of AEs to BNT162b2/Pfizer vaccination progressively 199 200 reduced across all doses. Nevertheless, moderate-to-severe AEs were markedly more common in our cohort compared to the COV-BOOST trial that used the same AE grading 201 202 system following third/booster doses of BNT162b2/Pfizer (AEs<5%;n=96)<sup>[16]</sup>. Our finding of progressive reductions in AEs across successive doses contrasts with both our prior work 203 (showing AEs increased between doses one and two<sup>[10]</sup>) and a recent Israeli stud showing the 204 opposite effect<sup>[17]</sup>. This might have occurred because either the present work involved a new 205 206 sample of HCWs (hence individual differences) or HCWs becoming more accustomed to 207 vaccine-associated AEs over time. Similarly, another surprising result was that gender did not appear to influence AEs, whereas our past studies have consistently shown females to report 208 more AEs following doses one and two of BNT162b2/Pfizer vaccination<sup>[9,10]</sup>. Younger 209 210 participants in the present study reported more AEs following the third/booster 211 BNT162b2/Pfizer dose, and the influenza vaccine, the former finding being consistent with our and other's prior work<sup>[9,10,20]</sup>. 212

213

Our second key finding was that the effect of prior COVID-19 on vaccine-associated AEs, was again carried over to the third/booster BNT162b2/Pfizer dose in terms of increased AEs. Nevertheless, the presence of self-reported OCS did not seem to impact AEs to BNT162b2/Pfizer vaccination at any of the dosage timepoints, although our sample of HCWs with OCS was notably small.

219

Regarding the effect of influenza vaccination on AEs experienced around the time of the third/booster BNT162b2/Pfizer dose, our analysis was somewhat limited by the small number of HCWs that received their influenza vaccine within 7 days of t BNT162b2/Pfizer vaccination (n=56). Analyses did however show that HCWs in this subgroup reported similar numbers/levels of AEs compared to individuals who received vaccines more than 7 days apart. This supports previous safety data, which found no worse AEs reported following concomitant administration of influenza with doses one or two of COVID-19 vaccines<sup>[13,14]</sup>.

227

228 Limitations of the present work include the large sample imbalance for participant gender (85%) 229 female), and the retrospective recall (up to 12 months) of AEs in the present study. Given that 230 vaccine safety plays a central role in people's decision to accept a vaccination, our present work has implications for vaccine hesitancy<sup>[18-20]</sup>. We found that BNT162b2/Pfizer-related AEs 231 232 diminished with each successive dose and were no worse than the AEs reported by HCWs following influenza vaccine, which has been widely accepted for many years. Our present work 233 also provides preliminary data to support concomitant administration of the third/booster 234 BNT162b2/Pfizer vaccination alongside the influenza vaccine. 235

236

## 237 5. Conclusion

Prior history of COVID-19 was associated with increased AEs to both BNT162b2/Pfizer vaccination (at all three dosage points). The presence of OCS and female gender had no impact on AEs to BNT162b2/Pfizer or influenza vaccination, though younger HCWs experienced more AEs. Lastly, AEs were no worse in HCWs who received concomitant booster BNT162b2/Pfizer and influenza vaccines.

243

## 245 **Contributors**

- 246 DRC/JR/RKR conceived the study and DRC is chief investigator of CHOIS. RKR acted as site
- 247 principal investigator. DRC/RKR/CW contributed to the study protocol, design, and data
- collection. JR did the statistical analysis. RKR/JR/DRC prepared the manuscript. All authors
- 249 critically reviewed and approved the final version.
- 250

# 251 Funding Sources

- 252 The CHOIS study was supported by the North East and North Cumbria Academic Health
- 253 Sciences Network (AHSN).
- 254
- 255 Conflict of Interest
- 256 No conflicts of interest.
- 257

# 258 Acknowledgements

- 259 We would like to thank the CHOIS research team, John Rouse and the North East and North
- 260 Cumbria NIHR for assistance with the survey.
- 261

# 262 Data Availability

All data will be made available upon request.

#### 265 **References**

- Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
   Covid-19 Vaccine. *N Engl J Med* 2020; 28: 2603-3615. doi: https://doi.org/10.1056/NEJMoa2034577.
- 269 2. Baden LER, El Sahly HM, Essink B et al. Efficacy and Safety of the mRNA-1273 SARS-Med. 270 CoV-2 Vaccine. Ν Engl J 2021; 384 (5): 403-416. doi: https://doi.org/10.1056/NEJMoa2035389. 271
- Voysey M, Clemens SAC, Madhi SA et al. Safety and efficacy of the ChAdOx1 nCoV 19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
   controlled trials in Brazil, South Africa, and the UK. *Lancet.* 2021;397(10269):99-111.
   doi: https://doi.org/10.1016/S0140-6736(20)32661-1.
- Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA
   COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported
   symptoms from healthcare workers. *Int J Infect Dis.* 2021;106:376-381. doi:
   https://doi.org/10.1016/j.ijid.2021.04.047.
- 5. Krammer F, Srivastava K, Alshammary H et al. Antibody Responses in Seropositive
  Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med*.
  2021;384(14):1372-1374. doi: https://doi.org/10.1056/NEJMc2101667.
- 283 6. Tré-Hardy M, Cupaiolo R, Papleux E et al. Reactogenicity, safety and antibody
  284 response, after one and two doses of mRNA-1273 in seronegative and seropositive
  285 healthcare workers. *J Infect.* 2021; 83(2):237–79. doi:
  286 https://doi.org/10.1016/j.jinf.2021.03.025.
- Ebinger JE, Fert-Bober J, Printsev I et al. Antibody responses to the BNT162b2 mRNA
   vaccine in individuals previously infected with SARS-CoV-2. *Nat Med*. 2021;27(6):981 984. doi: https://doi.org/10.1038/s41591-021-01325-6.
- 8. Mathioudakis AG, Ghrew M, Ustianowski A et al. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. *Life (Basel)*.
   2021;11(3):249. https://doi.org/10.3390/life11030249.

- Raw RK, Kelly CA, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection, but
   not Long-COVID, is associated with increased adverse events following
   BNT162b2/Pfizer vaccination. *J Infect*. 2021:S0163-4453(21)00277-2. doi:
   https://doi.org/10.1016/j.jinf.2021.05.035.
- 297 10. Raw RK, Rees J, Kelly CA, Wroe C, Chadwick DR. Prior COVID-19 infection is
  298 associated with increased Adverse Events (AEs) after the first, but not the second,
  299 dose of the BNT162b2/Pfizer vaccine. *Vaccine*. 2022; 40(3):418-423. doi:
  300 https://doi.org/10.1016/j.vaccine.2021.11.090.
- 301 11. National Institute of Clinic Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), Royal College of General Practitioners (RCGP). 2021. COVID-19 302 303 rapid guideline: managing the long-term effects of COVID-19. https://www.guidelines.co.uk/infection/nice-long-covid-guideline/455728.article 304 305 (accessed 25 July 2022).
- United Kingdom Government. Coronavirus (COVID-19) in the UK: Vaccinations in
   United Kingdom., 2022. https://coronavirus.data.gov.uk/details/vaccinations
   (accessed 25 July 2022).
- 13. Toback S, Galiza E, Cosgrove C et al. CoV-302 Study Group. Safety, immunogenicity,
  and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal
  influenza vaccines: an exploratory substudy of a randomised, observer-blinded,
  placebo-controlled, phase 3 trial. *Lancet Respir Med.* 2022;10(2):167-179. doi:
  https://doi.org/10.1016/S2213-2600(21)00409-4.
- 14. Lazarus R, Baos S, Cappel-Porter H et al. Safety and immunogenicity of concomitant 314 administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal 315 influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, 316 controlled. 2021;398(10318):2277-2287. 317 phase 4 trial. Lancet. doi: https://doi.org/10.1016/S0140-6736(21)02329-1. 318

- 15. Food and Drug Administration. Guidance for Industry Toxicity Grading Scale for
   Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical
   Trials. 2021. https://www.fda.gov/media/73679/download (accessed July 25, 2022).
- 16. Munro APS, Janani L, Cornelius V et al. Safety and immunogenicity of seven COVID-
- 323 19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or
- 324 BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled,
- phase 2 trial. *Lancet.* 2021; 398: 2258–76. doi: https://doi.org/10.1016/S0140 6736(21)02717-3.
- Merav Mofaz, Matan Yechezkel, Grace Guan et al. Self-Reported and Physiologic
   Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose. *Emerg Infect Dis*. 2022. 28(7): 1375-1383. doi: https://doi.org/10.3201/eid2807.212330.
- 18. Freeman D, Loe BS, Chadwick A et al. COVID-19 vaccine hesitancy in the UK: the
   Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. *Psychol Med.* 2020:1-15. doi: https://doi.org/10.1017/S0033291720005188.
- Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. *Nat Med.* 2021. doi: https://doi.org/10.1038/s41591-021-01459-7.
- 20. Robertson E, Reeve KS, Niedzwiedz CL et al. Predictors of COVID-19 vaccine
  hesitancy in the UK household longitudinal study. *Brain Behav Immun*. 2021;94:41-50.
  doi: https://doi.org/10.1016/j.bbi.2021.03.008.

338

339

340

# 343 **Figures and Captions**





Figure 1. Frequency of AEs by Vaccine Type, Prior COVID-19 Status and Interval Between Doses. A. Number of AEs according to previous COVID-19 history, for all three BNT162b2/Pfizer doses. B. Number of AEs according to previous COVID-19 history for BNT162b2/Pfizer third/booster dose and the seasonal influenza vaccine. C. Number of AEs according associated with the influenza vaccine versus BNT162b2/Pfizer third/booster dose for those HCWs who had these vaccines  $\leq$  or > 7 days apart.

362



□ No Prior Symptoms □ Prior Covid Symptoms

Figure 2. *Moderate and Severe AEs by COVID-19 Status*: Percentage of cases reporting
moderate or severe AEs (95% CI) following BNT162b2/Pfizer third/booster dose in those with
and without a history of COVID-19. N & V: nausea and vomiting.

#### **Tables and Captions**

### 

	Male	Female	р	d [95% C.I.]
	(n=80)	(n=454)		
Age	48.7 (11.5)	49.6 (10.7)	-	-
BNT162b2/Pfizer Dose 1	2.84 (2.85)	2.86 (2.75)	0.95	0.008 [-0.23 – 0.25]
BNT162b2/Pfizer Dose 2	2.44 (2.90)	2.55 (2.80)	0.74	0.04 [-0.2 – 0.28]
BNT162b2/Pfizer Dose 3	0.99 (1.97)	1.43 (2.01)	0.07	0.22 [-0.02 – 0.46]
Influenza	0.78 (1.79)	0.76 (1.48)	0.90	- 0.02 [-0.26 – 0.23]

Table 1. Number of AEs by Participant Gender and Vaccine Dose: Mean (S.D) number

of AEs reported by male versus female HCWs for all three BNT162b2/Pfizer doses and the seasonal Influenza vaccine.

	Dose 3	
	Odds Ratio	р
	(95% C.I.)	
Fever	1.44 (0.55 3.81)	>.99
Fatigue	2.37 (1.32 4.27)	<.001
Myalgia	2.25 (1.18 4.28)	0.001
Arthralgia	2.10 (0.98 4.46)	0.06
Lymphadenopathy	0.79 (0.79 1.40)	>.99
Local Pain	1.43 (0.77 2.65)	>.99
Local Redness	2.56 (0.77 8.53)	0.33
Local Swelling	3.15 (0.82 12.11)	0.18
Nausia & Vomiting	0.51 (0.12 2.12)	>.99
Diarrhoea	1.49 (0.23 9.47)	>.99
Headache	2.03 (1.10 3.77)	0.011

- 391 Table 2. Moderate and Severe AEs by COVID-19 Status: Percentage of cases reporting
- 392 moderate or severe AEs following BNT162b2/Pfizer third/booster dose (95% CI) in those with
- and without a history of COVID-19 (the former including OSC).

394